Sanne Samuels1, Vivian M Spaans, Michelle Osse, Lex A W Peters, Gemma G Kenter, Gertjan J Fleuren, Ekaterina S Jordanova. 1. *Department of Gynaecology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Center Gynaecology Oncology Amsterdam (CGOA), Department of Gynaecology, Netherlands Cancer Institute, Amsterdam, †Department of Gynaecology and Obstetrics, Leiden University Medical Center, Leiden, the Netherlands, ‡Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands; and §Center Gynaecological Oncology Amsterdam (CGOA), Department of Obstetrics and Gynaecology, VU University Medical Centre, Amsterdam, the Netherlands.
Abstract
OBJECTIVES: Human leukocyte antigen (HLA) class II antigens are expressed on antigen-presenting cells, that is, macrophages, dendritic cells, and B lymphocytes. Under the influence of IFN-γ, HLA class II molecules can also be expressed on T lymphocytes, epithelial and endothelial cells. In addition, HLA class II antigens can be expressed in a variety of malignancies; however, the link with prognosis and ultimately patient survival is controversial. METHODS: The pattern of HLA-DRA expression in cervical carcinoma was studied using immunohistochemistry. In total, 124 cervical carcinomas were examined, of which 60 (48.4%) were squamous cell carcinomas and 64 (51.6%) were adenocarcinomas. RESULTS: In squamous cell carcinoma, HLA-DRA was expressed in 41 (68.3%) of 60 tumors, whereas in adenocarcinoma, HLA-DRA was expressed in 60 (93.8%) of 64 tumors (P < 0.001). In adenocarcinoma, HLA-DRA expression was associated with an increased disease-free survival (211.0 ± 13.0 vs 53.3 ± 30.5 months; P = 0.004) and disease-specific survival (226.45 ± 11.5 vs 75.8 ± 27.6 months; P = 0.002). CONCLUSIONS: Upregulation of HLA-DRA is significantly related to an increased disease-free and disease-specific survival in cervical adenocarcinoma. These data warrant further analysis of the functional role of HLA-DRA in these tumors.
OBJECTIVES:Human leukocyte antigen (HLA) class II antigens are expressed on antigen-presenting cells, that is, macrophages, dendritic cells, and B lymphocytes. Under the influence of IFN-γ, HLA class II molecules can also be expressed on T lymphocytes, epithelial and endothelial cells. In addition, HLA class II antigens can be expressed in a variety of malignancies; however, the link with prognosis and ultimately patient survival is controversial. METHODS: The pattern of HLA-DRA expression in cervical carcinoma was studied using immunohistochemistry. In total, 124 cervical carcinomas were examined, of which 60 (48.4%) were squamous cell carcinomas and 64 (51.6%) were adenocarcinomas. RESULTS: In squamous cell carcinoma, HLA-DRA was expressed in 41 (68.3%) of 60 tumors, whereas in adenocarcinoma, HLA-DRA was expressed in 60 (93.8%) of 64 tumors (P < 0.001). In adenocarcinoma, HLA-DRA expression was associated with an increased disease-free survival (211.0 ± 13.0 vs 53.3 ± 30.5 months; P = 0.004) and disease-specific survival (226.45 ± 11.5 vs 75.8 ± 27.6 months; P = 0.002). CONCLUSIONS: Upregulation of HLA-DRA is significantly related to an increased disease-free and disease-specific survival in cervical adenocarcinoma. These data warrant further analysis of the functional role of HLA-DRA in these tumors.
Authors: Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer Journal: Head Neck Date: 2018-12-14 Impact factor: 3.147
Authors: Dieuwke L Marvin; Vivian M Spaans; Cor D de Kroon; Roderick C Slieker; Maryam Khelil; Peter Ten Dijke; Laila Ritsma; Ekaterina S Jordanova Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738
Authors: Debbie M Ferns; A Marijne Heeren; Sanne Samuels; Maaike C G Bleeker; Tanja D de Gruijl; Gemma G Kenter; Ekaterina S Jordanova Journal: J Immunother Cancer Date: 2016-11-15 Impact factor: 13.751
Authors: Marlies Schrevel; Willem E Corver; Margit E Vegter; Natalja T Ter Haar; Enno J Dreef; Jogchum J Beltman; Gemma Kenter; Tjalling Bosse; Cornelis D de Kroon; Ekaterina S Jordanova Journal: Oncotarget Date: 2017-09-18